Orphan designation: Dersimelagon Treatment of erythropoietic protoporphyria, 16/03/2022 Positive

Data Quality Framework for EU medicines regulation

Guidance on the anonymisation of protected personal data and assessment of commercially confidential information during the preparation of RMPs (main body and annexes 4 and 6)

Human medicines European public assessment report (EPAR): Amglidia, glibenclamide, Date of authorisation: 24/05/2018, Revision: 8, Status: Authorised

Frequently asked questions on medicinal products development and assessment involving companion diagnostic (CDx)

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Presentation - The EU EU health policy Pharmaceutical Reform - Lilia Luchianov (DG SANTE, EC)

Guideline on specific adverse reaction follow-up questionnaires (Specific AR FUQ)

Proposed invented name(s) request form for veterinary medicinal products